Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from ImageneBio ( (IMA) ).
On October 10, 2025, ImageneBio announced the resignation of their Chief Financial Officer, Jotin Marango, M.D., Ph.D., effective October 20, 2025. The company clarified that his departure was not due to any disagreement, and they plan to search for his replacement, indicating a potential shift in their financial leadership.
The most recent analyst rating on (IMA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on ImageneBio stock, see the IMA Stock Forecast page.
Spark’s Take on IMA Stock
According to Spark, TipRanks’ AI Analyst, IMA is a Neutral.
Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
To see Spark’s full report on IMA stock, click here.
More about ImageneBio
Average Trading Volume: 56,224
Technical Sentiment Signal: Sell
Current Market Cap: $92.47M
For detailed information about IMA stock, go to TipRanks’ Stock Analysis page.